Click to reveal the search form
Close the search form
Menu

National Institutes of Health

Biomedical research funded by the National Institutes of Health (NIH) and performed at research universities helps assure U.S. leadership in the life sciences revolution of the 21st Century. Putting NIH on a sustained pathway to restore its purchasing power after a decade worth of loss to inflation and budget cuts is critical to sustaining the extraordinary progress in the improvement of human health of the past decades. Investment in NIH will continue to create jobs and strengthen the workforce, improve the lives—and quality of life—of millions of current and future patients, and help assure continuing U.S. economic and national security.

Sustained investment in biotechnology and genomics is crucial to the development of novel therapies for diseases, including: cancer, Alzheimer's, autism, and diabetes. The NIH also responds rapidly to public health emergencies and in support of biodefense, such as in the case of Ebola, Zika, and COVID-19.

 

FY16: National Institutes of Health

AAU urges Congress to provide $32 billion for the National Institutes of Health.
Agency Budgets | Fact Sheets | Federal Budget | FY16 | National Institutes of Health

CPR Letter to Congress Strongly Endorses Peer Review at NIH

We stand united in our support for the NIH, its mission, and its world-renowned peer review process.
Letters | Merit Review | National Institutes of Health

COGR, AAU Comment on Proposed NIH Guidance on Significant Changes to Ongoing Animal Activities

COGR and AAU comment on the National Institutes of Health’s Office of Laboratory Animal Welfare (OLAW) guidance concerning significant changes in an approved animal protocol.
Letters | Research Administration & Regulation | National Institutes of Health

AAU Executive Committee Expresses Strong Support for Federal Funding of Social and Behavioral Sciences Research

Statement by the Executive Committee of the Association of American Universities on the importance of the federal investment in research in the social and behavioral sciences.
Agency Budgets | Statements | National Institutes of Health

AAU, COGR Submit Comments on Draft Dual-Use Research Policy

AAU, COGR comments to Dr. Franca R. Jones, Assistant Director—Chemical and Biological Countermeasures, Office of Science and Technology Policy, on the draft document "United States Government Policy for Institutional Oversight of Life Sciences Dual Use Research of Concern (DURC)."
Letters | Reducing Regulatory Burden | Biological & Chemical Security | Science & Security | National Institutes of Health

AAU Comments on NIH Proposals on the Biomedical Research Workforce

AAU responds to National Institutes of Health Notice Number: NOT-OD-13-045.
Letters | Research Administration & Regulation | National Institutes of Health

Community Letter Details Dangers of Further Cuts to NIH Budget

Organizations and institutions expressed concern about the impact of continued cuts, including sequestration, funding shortfalls in fiscal years 2013 and 2014, and the threat of additional cuts to offset the debt ceiling, on medical research supported by NIH, and the subsequent negative consequences for the health of all Americans.
Agency Budgets | Letters | Federal Budget | Fiscal Policy | National Institutes of Health

House Members Ask NIH to Implement Proof-of-Concept Pilot Program

Congress writes to express strong support for the NIH proof-of-concept pilot program authorized by the SBIR-STTR reauthorization included in the defense authorization bill passed in December, 2011. 
Agency Budgets | Letters | Technology Transfer | National Institutes of Health | Innovation and Competitiveness

AAU Response to NIH Director on Managing NIH Resources

AAU Response to NIH Director on managing NIH fiscal resources.
Agency Budgets | Recommendation | National Institutes of Health

AAU Submits Comments on OSTP Bioeconomy Blueprint

The Association of American Universities (AAU), representing 61 leading public and private research universities, would like to thank the Office of Science and Technology Policy (OSTP) for this opportunity to provide comments on the Bioeconomy Blueprint.
Letters | Reducing Regulatory Burden | Costs of Research (F&A Costs) | Technology Transfer | Research Administration & Regulation | National Institutes of Health | Innovation and Competitiveness